Actuate Therapeutics (ACTU) Competitors $6.76 -0.30 (-4.18%) As of 01:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends ACTU vs. XERS, MGTX, QURE, IMTX, ORIC, MNMD, ANAB, PGEN, KALV, and CGEMShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include Xeris Biopharma (XERS), MeiraGTx (MGTX), uniQure (QURE), Immatics (IMTX), ORIC Pharmaceuticals (ORIC), Mind Medicine (MindMed) (MNMD), AnaptysBio (ANAB), Precigen (PGEN), KalVista Pharmaceuticals (KALV), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. Xeris Biopharma MeiraGTx uniQure Immatics ORIC Pharmaceuticals Mind Medicine (MindMed) AnaptysBio Precigen KalVista Pharmaceuticals Cullinan Therapeutics Actuate Therapeutics (NASDAQ:ACTU) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment. Does the media favor ACTU or XERS? In the previous week, Xeris Biopharma had 4 more articles in the media than Actuate Therapeutics. MarketBeat recorded 5 mentions for Xeris Biopharma and 1 mentions for Actuate Therapeutics. Xeris Biopharma's average media sentiment score of 0.48 beat Actuate Therapeutics' score of -0.02 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ACTU or XERS? Xeris Biopharma has a consensus price target of $5.15, suggesting a potential upside of 19.63%. Given Xeris Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has stronger earnings & valuation, ACTU or XERS? Actuate Therapeutics has higher earnings, but lower revenue than Xeris Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$24.75MN/AN/AXeris Biopharma$187.36M3.43-$62.26M-$0.45-9.57 Does the MarketBeat Community believe in ACTU or XERS? Xeris Biopharma received 144 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformActuate TherapeuticsN/AN/AXeris BiopharmaOutperform Votes14469.90% Underperform Votes6230.10% Is ACTU or XERS more profitable? Actuate Therapeutics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A N/A Xeris Biopharma -33.69%N/A -17.38% Do insiders & institutionals have more ownership in ACTU or XERS? 42.8% of Xeris Biopharma shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryXeris Biopharma beats Actuate Therapeutics on 9 of the 12 factors compared between the two stocks. Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$132.53M$7.21B$5.83B$8.35BDividend YieldN/A2.78%4.89%4.00%P/E RatioN/A6.1625.0619.30Price / SalesN/A223.09376.96115.39Price / CashN/A65.6738.0534.62Price / BookN/A6.527.424.28Net Income-$24.75M$138.98M$3.18B$246.62M7 Day Performance-2.09%-0.80%-1.47%-2.35%1 Month Performance-23.07%-8.20%-6.57%-7.66%1 Year PerformanceN/A-11.23%14.61%4.25% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate TherapeuticsN/A$6.76-4.2%N/AN/A$131.94MN/A0.0010Gap DownXERSXeris Biopharma3.3887 of 5 stars$3.76+0.3%$5.15+37.0%+22.4%$560.55M$187.36M-8.36290Earnings ReportNews CoverageGap UpMGTXMeiraGTx4.7269 of 5 stars$7.17-1.8%$23.50+227.8%+8.4%$560.36M$13.93M-5.93300News CoverageQUREuniQure3.6103 of 5 stars$11.48-10.6%$40.00+248.4%+139.9%$559.57M$28.59M-2.31500Analyst ForecastInsider TradeShort Interest ↓Analyst RevisionNews CoverageGap DownIMTXImmatics2.4005 of 5 stars$4.65+1.1%$16.67+258.4%-60.6%$555.02M$58.44M-7.05260Short Interest ↓News CoverageNegative NewsHigh Trading VolumeORICORIC Pharmaceuticals4.3998 of 5 stars$7.56-1.6%$18.71+147.5%-48.7%$536.99MN/A-4.1580MNMDMind Medicine (MindMed)2.2211 of 5 stars$7.18-5.9%$26.33+266.8%+7.4%$526.51MN/A-3.1840Earnings ReportNews CoverageGap DownANABAnaptysBio3.1072 of 5 stars$17.20-7.5%$36.20+110.5%-33.9%$523.38M$57.17M-2.83100Earnings ReportAnalyst ForecastAnalyst RevisionGap DownPGENPrecigen3.8142 of 5 stars$1.75-8.4%$7.00+300.0%+19.9%$512.52M$3.96M-3.18190Positive NewsKALVKalVista Pharmaceuticals4.7738 of 5 stars$10.35+3.2%$23.80+130.0%-17.0%$511.48MN/A-2.84100Upcoming EarningsShort Interest ↓High Trading VolumeCGEMCullinan Therapeutics2.1503 of 5 stars$8.72-3.4%$32.50+272.7%-53.4%$507.77MN/A-3.0730Earnings ReportAnalyst Revision Related Companies and Tools Related Companies XERS Competitors MGTX Competitors QURE Competitors IMTX Competitors ORIC Competitors MNMD Competitors ANAB Competitors PGEN Competitors KALV Competitors CGEM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACTU) was last updated on 3/6/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes liveElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredTrump’s revenge could mean 22% yields for youDonald Trump is turning up the heat on America's rivals. His "maximum pressure" strategy is back in full fo...Investors Alley | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredTrillion-Dollar Crypto PlayAI is Creating Fortunes… (but not where you think!) Bryce Paul and the team at Crypto101 just released a br...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACTU Stock Alerts